by Crestone, Inc. | May 18, 2018 | Events
2018 NTM & Bronchiectasis Physician/Patient Presentation Details Crestone presents a poster on NTM drug development at the 2018 NTM & Bronchiectasis Physician/Patient Conference.
by Crestone, Inc. | Mar 11, 2018 | Events
Crestone presents a poster at New Antibacterial Discovery and Development Gordon Research Conference, Ventura Beach, CA: CRS3123, a novel drug candidate for the treatment of Clostridium difficile infection, is safe, well-tolerated and exhibits high intestinal levels...
by Crestone, Inc. | Dec 20, 2017 | Press Releases
Dec 20, 2017 – Announcement: Crestone enters a Research Agreement with Colorado University at Boulder to develop efflux pump modulators for the treatment of Gram-negative infections, thus adding a fourth program to its pipeline.
by Crestone, Inc. | Oct 30, 2017 | Events
Crestone presents two posters at Keystone Symposia (Santa Fe, NM). Optimization and Lead Selection of Benzothiazole-adamantyl Amide Analogs toward a Novel Antimycobacterial AgentPhase 1 Clinical Trial Results on the Safety and Pharmacokinetics of CRS3123, a Novel...
by Crestone, Inc. | Oct 18, 2017 | Events
Crestone presents an invited slide talk at Clinical & Pharmaceutical Microbiology, Rome, Italy: CRS3123, a Novel Narrow-Spectrum Agent in Clinical Development to Treat C. difficile Infections.
